# Combi-TED (NCT04884282)

> Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04884282
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Fondazione Ricerca Traslazionale
- Conditions: Metastatic Non Small Cell Lung Cancer
- Interventions: Tedopi; Nivolumab; Docetaxel
- Enrollment: 105
- Primary outcome: 1-year Survival Rate

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 5

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=combi-ted-nct04884282